Meclozine + Pyridoxine

Generic Medicine Info
Indications and Dosage
Pregnancy-associated nausea and vomiting
Adult: As combination preparation containing meclozine 25 mg and pyridoxine 50 mg per tablet: 1 tablet at night.
Special Precautions
Prostate hypertrophy, obstruction of bladder neck, narrow angle glaucoma, pyloric stenosis. May impair ability to drive or operate machinery. Pregnancy.
Adverse Reactions
Drowsiness, thickening of bronchial secretions, dry mouth, fatigue, blurred vision.
Drug Interactions
Meclozine: Additive effects with CNS depressants, neuroleptics, anticholinergics, alcohol.
Lab Interference
Pyridoxine: May cause false-positive results for urobilinogen in the spot test using Ehrlich's reagent.
Description: Meclozine hydrochloride, a piperazine derivative, is a sedating antihistamine with antimuscarinic properties. It is mainly used in the prevention and treatment of nausea and vomiting associated with a variety of conditions.
Onset: Meclozine: 1 hr
Duration: Meclozine: 8-24 hr
Absorption: Pyridoxine: Readily absorbed from GI tract except in malabsorption syndromes or following gastric resection.
Metabolism: Pyridoxine: Converted to pyridoxal phosphate and pyridoxamine phosphate in the liver; riboflavin needed for further conversion of pyridoxine phosphate to pyridoxal phosphate which are the principal forms of the vitamin in the blood. Pyridoxal is further oxidised to 4-pyridoxic acid in liver.
Excretion: Meclozine: Plasma half-life: 6 hr. Pyridoxine: Excreted in urine (4-pyridoxic acid).
Store below 25°C.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Meclozine + Pyridoxine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in